$MGNX
MACROGENICS INC Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000112534521000115 Filed on November 02, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$14.15M	$15.66M	$52.70M
YoY Change	-73.16%	-14.19%	109.19%
Cost Of Revenue	$947.0K	$1.665M
YoY Change
Gross Profit	$13.20M	$14.00M
YoY Change		-23.32%
Gross Profit Margin	93.31%	89.37%
Selling, General & Admin	$15.58M	$17.16M	$12.60M
YoY Change	23.67%	76.92%	5.88%
% of Gross Profit	118.05%	122.6%
Research & Development	$55.85M	$49.82M	$42.30M
YoY Change	32.04%	11.57%	-18.65%
% of Gross Profit	423.13%	355.95%
Depreciation & Amortization	$2.952M	$2.796M	$2.890M
YoY Change	2.15%	-5.54%	5.86%
% of Gross Profit	22.36%	19.98%
Operating Expenses	$71.44M	$49.82M	$54.90M
YoY Change	30.12%	11.57%	-13.95%
Operating Profit	-$58.24M	-$52.99M
YoY Change		46.64%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$214.0K	$101.0K	$100.0K
YoY Change	114.0%	9.78%	-98.8%
Pretax Income	-$58.02M	-$52.89M	-$2.100M
YoY Change	2662.95%	46.91%	-93.09%
Income Tax
% Of Pretax Income
Net Earnings	-$58.02M	-$52.89M	-$2.100M
YoY Change	2662.95%	46.73%	-93.09%
Net Earnings / Revenue	-410.14%	-337.67%	-3.98%
Basic Earnings Per Share		-$0.86
Diluted Earnings Per Share	-$946.6K	-$0.86	-$37.37K
COMMON SHARES
Basic Shares Outstanding	61.26M shares	61.17M shares	56.20M shares
Diluted Shares Outstanding		61.17M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$243.6M	$298.9M	$272.5M
YoY Change	-10.6%	6.48%	26.27%
Cash & Equivalents	$123.5M	$190.5M	$181.1M
Short-Term Investments	$120.1M	$108.4M	$91.40M
Other Short-Term Assets	$21.17M	$18.06M	$17.00M
YoY Change	24.53%	70.4%	50.44%
Inventory	$4.388M	$3.979M	$0.00
Prepaid Expenses	$21.17M		$16.98M
Receivables	$10.39M	$13.76M	$23.08M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$279.6M	$334.7M	$312.6M
YoY Change	-10.57%	7.94%	30.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$37.68M	$38.68M	$42.23M
YoY Change	-10.77%	-6.61%	-12.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$18.01M	$18.78M	$23.92M
YoY Change	-24.72%	-17.96%	-2.37%
Total Long-Term Assets	$55.69M	$57.46M	$66.15M
YoY Change	-15.82%	-10.65%	-9.03%
TOTAL ASSETS
Total Short-Term Assets	$279.6M	$334.7M	$312.6M
Total Long-Term Assets	$55.69M	$57.46M	$66.15M
Total Assets	$335.2M	$392.2M	$378.7M
YoY Change	-11.48%	4.75%	21.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.50M	$6.170M	$8.031M
YoY Change	93.0%	40.87%	86.42%
Accrued Expenses	$33.76M	$41.86M	$34.20M
YoY Change	-1.3%	28.11%	26.01%
Deferred Revenue	$20.65M	$16.31M	$4.456M
YoY Change	363.33%	76.2%	-58.36%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$74.58M	$68.86M	$50.67M
YoY Change	47.18%	37.4%	12.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$258.0K	$258.0K	$0.00
YoY Change		-88.51%
Total Long-Term Liabilities	$258.0K	$258.0K	$0.00
YoY Change		-88.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$74.58M	$68.86M	$50.67M
Total Long-Term Liabilities	$258.0K	$258.0K	$0.00
Total Liabilities	$95.63M	$100.7M	$82.86M
YoY Change	15.41%	21.65%	1.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$973.9M	-$915.9M	-$771.8M
YoY Change	26.19%	18.99%	20.21%
Common Stock	$1.214B	$1.207B	$1.068B
YoY Change	13.67%	13.76%	22.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$239.6M	$291.4M	$295.9M
YoY Change
Total Liabilities & Shareholders Equity	$335.2M	$392.2M	$378.7M
YoY Change	-11.48%	4.75%	21.2%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$58.02M	-$52.89M	-$2.100M
YoY Change	2662.95%	46.73%	-93.09%
Depreciation, Depletion And Amortization	$2.952M	$2.796M	$2.890M
YoY Change	2.15%	-5.54%	5.86%
Cash From Operating Activities	-$54.31M	-$14.80M	-$5.530M
YoY Change	882.08%	-42.39%	-85.46%
INVESTING ACTIVITIES
Capital Expenditures	-$1.375M	-$2.133M	-$3.560M
YoY Change	-61.38%	326.6%	184.8%
Acquisitions
YoY Change
Other Investing Activities	-$12.18M	-$484.0K	-$12.52M
YoY Change	-2.73%	-98.87%	-241.15%
Cash From Investing Activities	-$13.55M	-$2.617M	-$16.08M
YoY Change	-15.72%	-93.95%	-311.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	800.0K	18.97M	1.100M
YoY Change	-27.27%	-74.38%	279.31%
NET CHANGE
Cash From Operating Activities	-54.31M	-14.80M	-5.530M
Cash From Investing Activities	-13.55M	-2.617M	-16.08M
Cash From Financing Activities	800.0K	18.97M	1.100M
Net Change In Cash	-67.06M	1.561M	-20.51M
YoY Change	226.97%	-69.39%	-31.93%
FREE CASH FLOW
Cash From Operating Activities	-$54.31M	-$14.80M	-$5.530M
Capital Expenditures	-$1.375M	-$2.133M	-$3.560M
Free Cash Flow	-$52.93M	-$12.66M	-$1.970M
YoY Change	2587.01%	-49.71%	-94.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36112
	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1591613
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9704 Medical Center Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
	dei	City Area Code CityAreaCode	301
	dei	Local Phone Number LocalPhoneNumber	251-5172
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	MGNX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61258001	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190531000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181131000	USD
CY2021Q3	us-gaap	Investments Investments	108367000	USD
CY2020Q4	us-gaap	Investments Investments	91400000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13759000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23081000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	3979000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18062000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16982000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	334698000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	312594000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38684000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42225000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18778000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23924000	USD
CY2021Q3	us-gaap	Assets Assets	392160000	USD
CY2020Q4	us-gaap	Assets Assets	378743000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6170000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8031000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41859000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34198000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16314000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4456000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4521000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3988000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	68864000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	50673000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9575000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6926000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22025000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25260000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2021Q3	us-gaap	Liabilities Liabilities	100722000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	82859000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61254693	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56244771	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	613000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	562000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1206742000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1067150000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-915914000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-771821000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	291438000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	295884000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	392160000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	378743000	USD
CY2021Q3	us-gaap	Revenues Revenues	15662000	USD
CY2020Q3	us-gaap	Revenues Revenues	18253000	USD
	us-gaap	Revenues Revenues	63300000	USD
	us-gaap	Revenues Revenues	52192000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1665000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1704000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49823000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44656000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	158724000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	150901000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17161000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9732000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47431000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30181000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	68649000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	54388000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	207859000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	181082000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-52987000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-36135000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-144559000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-128890000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	101000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	92000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	466000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1238000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-52886000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-36043000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-144093000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-127652000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-15000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-14000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52890000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36058000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-144089000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-127666000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.86
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.42
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.42
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.49
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61169754	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61169754	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54463412	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54463412	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59494836	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59494836	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51176884	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51176884	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	295884000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5243000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	98200000	USD
CY2021Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2458000	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	18000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-51272000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	350531000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6113000	USD
CY2021Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2346000	USD
CY2021Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-10000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39935000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	319045000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6309000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19640000	USD
CY2021Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	-666000	USD
CY2021Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-52886000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	291438000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	230628000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4451000	USD
CY2020Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	162000	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	56000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-44724000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	190573000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5136000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	96512000	USD
CY2020Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2503000	USD
CY2020Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-55000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-46885000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	247784000	USD
CY2020Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-15000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6033000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5796000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	73981000	USD
CY2020Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	82000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-36043000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	291585000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-144093000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-127652000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8306000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9067000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1267000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	387000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	17714000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15419000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1602000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9322000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5582000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1080000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-654000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-5146000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1615000	USD
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-1931000	USD
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	137000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7744000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5499000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2701000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2113000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	14507000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4816000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	258000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2245000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89521000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106365000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	164780000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	151230000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	146550000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	161866000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4826000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2346000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23056000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8290000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117818000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	170494000	USD
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	5722000	USD
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	4757000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1563000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2011000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	121977000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	173240000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9400000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	75165000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181131000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126472000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190531000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201637000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	69000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	108371000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	108367000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	91407000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	91400000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	608000	USD
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	3095000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	276000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	3979000	USD
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1600000	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6358000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5832000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17714000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15419000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7258353	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.48
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1914846	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.86
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	302649	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	17.77
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	339961	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	19.12
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8530589	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.52
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19925000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5314252	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.76
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	10445000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8135407	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	21.62
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	18793000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.21
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.5
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3200000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	12400000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3900000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5400000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4500000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	14800000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	36300000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M6D

Files In Submission

Name	View Source	Status
0001125345-21-000115-index-headers.html	Edgar Link	pending
0001125345-21-000115-index.html	Edgar Link	pending
0001125345-21-000115.txt	Edgar Link	pending
0001125345-21-000115-xbrl.zip	Edgar Link	pending
exhibit31-1q32021.htm	Edgar Link	pending
exhibit31-2q32021.htm	Edgar Link	pending
exhibit32-1q32021.htm	Edgar Link	pending
exhibit32-2q32021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgnx-20210930.htm	Edgar Link	pending
mgnx-20210930.xsd	Edgar Link	pending
mgnx-20210930_cal.xml	Edgar Link	unprocessable
mgnx-20210930_def.xml	Edgar Link	unprocessable
mgnx-20210930_htm.xml	Edgar Link	completed
mgnx-20210930_lab.xml	Edgar Link	unprocessable
mgnx-20210930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MACROGENICS INC Stock $mgnx

2021 Q4 Form 10-Q Financial Statement

#000112534521000115 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MACROGENICS INC Stock $mgnx

2021 Q4 Form 10-Q Financial Statement

#000112534521000115 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MACROGENICS INC Stock $mgnx